Conciseness

The body is dense and directive throughout — it names exact tool calls, thresholds ("PRR >= 2.0, N >= 3, lower CI > 1.0"), and Naranjo scoring values without explaining concepts Claude already knows. Minor duplication between the ASCII workflow diagram and the per-phase summaries (each phase name/purpose appears twice) keeps it below a 5.

Actionability

Concrete, executable guidance dominates: specific tool function names (`FAERS_calculate_disproportionality`, `OpenTargets_get_drug_chembId_by_generic_name`), explicit signal criteria, Naranjo point scoring, and a decomposed Safety Signal Score ("FAERS signal strength (0-35), serious AEs (0-30), FDA label warnings (0-25), literature evidence (0-10)"). It falls short of a 5 because key execution detail (code examples, output templates, full classification table) is deferred to `PHASE_DETAILS.md` and `REPORT_TEMPLATE.md`, which do not exist in the bundle.

Workflow Clarity

Ten phases are clearly sequenced with an overview diagram, per-phase summaries, a flagged "CRITICAL PHASE", and an Edge Cases section covering failure modes ("`{error: {code: "NOT_FOUND"}}` is normal when a section does not exist", "No FAERS reports: Skip Phases 1-2") and a completeness checklist. Not a 5 because the validation/checklist mechanics and full scoring rubric are deferred to missing files, leaving the error-recovery loop implicit in SKILL.md itself.

Progressive Disclosure

The body correctly signals one-level-deep references ("See `PHASE_DETAILS.md` for full signal classification table"), but none of the four referenced files (`PHASE_DETAILS.md`, `REPORT_TEMPLATE.md`, `TOOL_REFERENCE.md`, `QUICK_START.md`) exist in the bundle — there are no references/, scripts/, or assets/ directories. Scored against the actual bundle structure per the judging guidelines, the deferred content is inaccessible, so navigation breaks exactly where the skill points the reader.

Specificity

Multiple concrete capabilities are named with their methods and outputs: "Detect and analyze adverse drug event signals using FDA FAERS reports, drug labels, and disproportionality statistics (PRR, ROR, IC)" plus "Generates quantitative safety signal scores (0-100) with evidence grading". Coverage of the domain is comprehensive and entirely free of vague filler.

Completeness

Both halves are explicit: the "what" states the detection methods, data sources, and output (quantitative 0-100 safety signal scores with evidence grading), and the "Use for" clause lists concrete triggers (post-market surveillance, pharmacovigilance, drug safety assessment, regulatory submissions, detecting rare AE signals not visible in clinical trials).

Trigger Term Quality

Strong natural terms a pharmacovigilance user would say: "post-market surveillance", "pharmacovigilance", "drug safety assessment", "regulatory submissions", "adverse drug event", "FAERS". Below a 5 because common lay/clinical synonyms like "side effects", "safety profile", or "drug safety comparison" are missing as trigger phrasings.

Distinctiveness Conflict Risk

The niche is clear and the statistical framing (FAERS, PRR/ROR/IC, signal scores) is distinct from generic analysis skills. Held at 4 because the body acknowledges a sibling skill "tooluniverse-pharmacovigilance" covering adjacent ground, and the description does not itself draw that boundary — a user asking broadly for "pharmacovigilance" could reasonably match either.